NeOnc Technologies Lists on Nasdaq, Expands Neuro-oncology Clinical Trials to India

Alongside its public listing, NeOnc announced a strategic partnership with CBCC Global Research, a leading clinical research organization, to expand its neuro-oncology clinical trials in India.

NeOnc Technologies, a licensed biotech startup at the University of South Carolina (USC) developing an intranasal drug delivery system for brain tumors, debuted on Nasdaq.

The milestone was celebrated on March 26 with the ringing of the opening bell, a significant achievement for both NeOnc and the USC Stevens Center for Innovation.

Strategic Partnership to Expand Clinical Trials

Alongside its public listing, NeOnc announced a strategic partnership with CBCC Global Research, a leading clinical research organization (CRO), to expand its neuro-oncology clinical trials.

This collaboration will add 30 FDA-compliant clinical research sites in India, significantly enhancing patient recruitment and accelerating the global development of NeOnc’s treatment.

NeOnc Technologies is built on research led by Dr. Thomas Chen, a neurosurgeon and tenured professor at Keck School of Medicine of USC.

The company is the first USC-licensed biotech firm to go public under agreements with USC Stevens. USC holds a minority equity interest of less than 5% in the company.

NeOnc’s primary focus is treating malignant gliomas with its proprietary drug, NEO100, an ultra-purified perillyl alcohol with cancer-fighting properties.

Following successful phase 1 clinical trials demonstrating safety and tolerance in 2019, phase 2 trials are now underway.

Ten clinical sites are currently recruiting patients, and the expansion into India through CBCC Global Research will further accelerate research efforts.

This development underscores the critical role of university research in driving medical breakthroughs from the lab to patient care.

Stay tuned for more such updates on Digital Health News.